Enveric Biosciences, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
ENVB$1.42+1.7%Stored close · as of Nov 6, 2026
Contents
Item 1. Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024
CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash | $2,849,816 | $2,241,026 |
| Prepaid expenses and other current assets | 457,556 | 493,558 |
| Total current assets | 3,307,372 | 2,734,584 |
| Other assets: | ||
| Property and equipment, net | 241,082 | 305,777 |
| Intangible assets, net | — | 42,182 |
| Total other assets | 241,082 | 347,959 |
| Total assets | $3,548,454 | $3,082,543 |
| LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,040,967 | $521,747 |
| Due to related parties | 99,875 | 232,891 |
| Accrued expenses and other current liabilities | 222,843 | 735,098 |
| Total current liabilities | 1,363,685 | 1,489,736 |
| Commitments and contingencies (Note 9) | - | - |
| Mezzanine equity | ||
| Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | — | — |
| Total mezzanine equity | — | — |
| Shareholders’ equity | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | — | — |
| Common Stock, $0.01 par value, 100,000,000 shares authorized, 3,026,028 and 678,002 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 30,260 | 6,780 |
| Additional paid-in capital | 113,506,692 | 108,255,049 |
| Accumulated deficit | (110,778,652) | (106,074,505) |
| Accumulated other comprehensive loss | (573,531) | (594,517) |
| Total shareholders’ equity | 2,184,769 | 1,592,807 |
| Total liabilities, mezzanine equity, and shareholders’ equity | $3,548,454 | $3,082,543 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Operating expenses | ||||
| General and administrative | $1,219,018 | $1,248,151 | $2,579,156 | $3,133,904 |
| Research and development | 1,260,051 | 565,001 | 2,006,422 | 1,071,156 |
| Depreciation and amortization | 39,980 | 84,779 | 121,004 | 170,188 |
| Total operating expenses | 2,519,049 | 1,897,931 | 4,706,582 | 4,375,248 |
| Loss from operations | (2,519,049) | (1,897,931) | (4,706,582) | (4,375,248) |
| Other (expense) income | ||||
| Other income | — | 18,572 | 2,565 | 40,009 |
| Interest (expense) income, net | (132) | (35) | (130) | 661 |
| Total other (expense) income | (132) | 18,537 | 2,435 | 40,670 |
| Net loss before income taxes | $(2,519,181) | $(1,879,394) | $(4,704,147) | $(4,334,578) |
| Income tax expense | — | — | — | (1,731) |
| Net loss | (2,519,181) | (1,879,394) | (4,704,147) | (4,336,309) |
| Other comprehensive loss | ||||
| Foreign currency translation | 24,473 | (14,652) | 20,986 | 3,254 |
| Comprehensive loss | $(2,494,708) | $(1,894,046) | $(4,683,161) | $(4,333,055) |
| Net loss per share - basic and diluted | $(0.97) | $(3.72) | $(2.15) | $(11.22) |
| Weighted average shares outstanding, basic and diluted | 2,595,728 | 505,857 | 2,191,084 | 386,310 |
ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
| Common Stock | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Loss · Total Shareholders’ Equity | |||||||
| Balance at January 1, 2025 | 678,002 | $6,780 | $108,255,049 | - | $(106,074,505) | $(594,517) | $1,592,807 |
| Issuance of Common Stock and Series A and B and prefunded warrants for cash, net of offering costs of $755,487 | 1,229,330 | 12,293 | 4,232,174 | — | — | 4,244,467 | |
| Issuance of common shares for vested RSAs | 14,586 | 146 | (146) | — | — | — | |
| Issuance of common shares for exercise of warrants | 462,336 | 4,623 | 70,421 | — | — | 75,044 | |
| Issuance of round up shares | 87,402 | 874 | (874) | — | — | — | |
| Stock-based compensation | — | — | 193,848 | — | — | 193,848 | |
| Foreign exchange translation loss | — | — | — | — | (3,487) | (3,487) | |
| Net loss | — | — | — | - | (2,184,966) | — | (2,184,966) |
| Balance at March 31, 2025 | 2,471,656 | $24,716 | $112,750,472 | - | $(108,259,471) | $(598,004) | $3,917,713 |
| Issuance of common shares for cash pursuant to ATM Agreement, net of offering costs of $179,714 | 554,372 | 5,544 | 549,960 | — | — | 555,504 | |
| Stock-based compensation | — | — | 206,260 | — | — | 206,260 | |
| Foreign exchange translation gain | — | — | — | — | 24,473 | 24,473 | |
| Net loss | — | — | — | - | (2,519,181) | — | (2,519,181) |
| Balance at June 30, 2025 | 3,026,028 | $30,260 | $113,506,692 | - | $(110,778,652) | $(573,531) | $2,184,769 |
ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
| Common Stock | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Additional Paid-In Capital | Subscription Receivable | Accumulated Deficit | Accumulated Other Comprehensive Loss | Total Shareholders’ Equity | |
| Balance at January 1, 2024 | 182,625 | $1,827 | $100,841,416 | $(1,817,640) | $(96,499,518) | $(569,749) | $1,956,336 |
| Common Stock sold under the Equity Distribution Agreement, net of offering costs of $583,713 | 111,200 | 1,112 | 1,807,677 | — | — | — | 1,808,789 |
| Issuance of direct offering shares | 15,246 | 152 | 322,301 | — | — | — | 322,453 |
| Exercise of Inducement Warrants for Common Stock | 130,267 | 1,303 | 2,675,677 | — | — | — | 2,676,980 |
| Proceeds from the subscription receivable related to the issuance of Inducement Warrants, net of offering costs of $12,821 | — | — | (12,821) | 280,500 | — | — | 267,679 |
| Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of Common Stock in abeyance | 46,934 | 469 | (469) | 1,537,140 | — | — | 1,537,140 |
| Stock-based compensation | — | — | 351,488 | — | — | — | 351,488 |
| Foreign exchange translation gain | — | — | — | — | — | 17,906 | 17,906 |
| Net loss | — | — | — | — | (2,456,915) | — | (2,456,915) |
| Balance at March 31, 2024 | 486,272 | $4,863 | $105,985,269 | $— | $(98,956,433) | $(551,843) | $6,481,856 |
| Stock-based compensation | — | — | 369,614 | — | — | — | 369,614 |
| Common Stock sold under the Purchase Agreement, net of offering costs of $82,850 | 8,334 | 84 | (84) | — | — | — | — |
| Issuance of direct offering shares | 30,534 | 306 | 448,534 | — | — | — | 448,840 |
| Issuance of common shares for vested RSU | 105 | 1 | (1) | — | — | — | — |
| Foreign exchange translation loss | — | — | — | — | — | (14,652) | (14,652) |
| Net loss | — | — | — | — | (1,879,394) | — | (1,879,394) |
| Balance at June 30, 2024 | 525,245 | $5,254 | $106,803,332 | $— | $(100,835,827) | $(566,495) | $5,406,264 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.